EFC16035: A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis (PERSEUS)

Grants and Contracts Details

StatusActive
Effective start/end date8/20/20 → 1/24/25

Funding

  • Sanofi Aventis US Inc: $106,221.00